Future options for disease intervention: important advances in phosphodiesterase 4 inhibitors Source: Eur Respir Rev 2007; 16: 105-112 Year: 2007
Combined inhalation of iloprost and the dual selective phosphodiesterase (PDE) inhibitor tolafentrine in a model of acute pulmonary hypertension Source: Eur Respir J 2001; 18: Suppl. 33, 198s Year: 2001
Effects of iloprost and the phosphodiesterase inhibitor tolafentrine on pulmonary vascular remodelling in chronic experimental pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 20s Year: 2003
Treatment effects of Rho-kinase (Rock) inhibition vs. phosphodiesterase-5 (PDE5) inhibition on cardiac function and metabolism in monocrotaline induced pulmonary arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 547s Year: 2006
Effects of phosphodiesterase 3/4 inhibition on matrixmetalloproteinases 2 and 9 in chronic experimental pulmonary hypertension Source: Eur Respir J 2004; 24: Suppl. 48, 435s Year: 2004
Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy Source: Eur Respir Rev 2009; 18: 35-41 Year: 2009
The use of combination therapy in pulmonary arterial hypertension: new developments Source: Eur Respir Rev 2009; 18: 148-153 Year: 2009
Adenosine deaminase – adenosine pathway in hemolysis-induced pulmonary hypertension Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010
Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2004; 24: 1007-1010 Year: 2004
RESPITE: Riociguat in pulmonary arterial hypertension patients with an inadequate response to phosphodiesterase type 5 inhibitors Source: International Congress 2016 – Clinic of pulmonary hypertension Year: 2016
Current medical therapies in pulmonary arterial hypertension Source: Eur Respir Mon 2012; 57: 26-41 Year: 2012
Partial reversal of experimental pulmonary hypertension by phosphodiesterase 3/4 inhibition Source: Eur Respir J 2006; 28: Suppl. 50, 804s Year: 2006
The selective Rho kinase inhibitor trans-6-((4-aminocyclohexyl)amino)-5-fluoro-2-methoxynicotinamide ameliorates experimental pulmonary hypertension Source: International Congress 2017 – Experimental PH Year: 2017
The selective phosphodiesterase 4 inhibitor, cilomilast, inhibits interleukin-8-induced pulmonary neutrophil accumulation in the rabbit Source: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001
Riociguat: an upcoming therapy in chronic thromboembolic pulmonary hypertension? Source: Eur Respir Rev 2009; 19: 68-71 Year: 2010
Adenosine 5’ – triphosphate (ATP) and adenosine 5' – monophosphate (AMP) challenge testing in current smokers and patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2003; 22: Suppl. 45, 414s Year: 2003
Comparison of acute hemodynamic effects of three different phosphodiesterase inhibitors in patients with pulmonary arterial hypertension Source: Eur Respir J 2004; 24: Suppl. 48, 705s Year: 2004
First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension Source: Eur Respir J 2009; 33: 785-792 Year: 2009
Phosphodiesterase-type 3 inhibitor potentiates cAMP generation and antiproliferative effects of treprostinil in pulmonary arterial smooth muscle cells from patients with pulmonary hypertension Source: Annual Congress 2010 - Pathobiology of pulmonary hypertension Year: 2010
Predictors of response to phosphodiesterase-5 inhibitors in pulmonary arterial hypertension Source: Virtual Congress 2021 – Therapy of pulmonary hypertension Year: 2021